Advertisement
Home »

Identification of Ovarian Cancer Patients Benefiting Most from Bevacizumab in the First-Line Setting Based on Tumor-Intrinsic Chemosensitivity

Jan 08, 2023

ABOUT THE CONTRIBUTORS

MORE ARTICLES BELOW

PW Weekly Newsletters

The latest articles and insights from your colleagues in your specialty(ies) of choice.


Advertisement
Advertisement
ad
ad
MORE ARTICLES BELOW

PW Weekly Newsletters

The latest articles and insights from your colleagues in your specialty(ies) of choice.

SUBSCRIBE NOW

View all newsletters

Advertisement